8 July 2025

ECO Animal Health Group plc

("ECO" or the "Company")

Share Repurchase, Notice of General Meeting and Notice of Results

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that it is today posting to shareholders a circular (the "Circular") which contains a notice of general meeting (the "Notice") and a form of proxy. The General Meeting will be held on 21 August 2025, to seek shareholders' approval for the Board to make limited on market purchases of the Company's ordinary shares of 5 pence each ("Ordinary Shares").

On 9 February 2025, the Company announced the disposal of certain non-core product lines. The board stated that it intends to use a portion the proceeds from the sale to purchase Ordinary Shares in the market to cover possible future vesting of employee share-based incentives including share options, long term incentive plans and the deferred bonus scheme.

Copies of the Circular, Form of Proxy and the Notice will be made available on the Company's website at www.ecoanimalhealth.com.

The Company also announces that it will issue its audited financial results for the year ended 31 March 2025 on 14 July 2025.

David Hallas, CEO, and Christopher Wilks, CFO, will host an in-person presentation and Q&A session for analysts at 11:00 BST on the day of results. There will be a dial-in option for those unable to attend in person.

For further information about the analyst presentation, please contact  [email protected].

In addition, David Hallas and Christopher Wilks will conduct a live online presentation of the results at 14:00 BST on 14 July 2025.  This event is open to all existing and potential shareholders and registration is free. Questions can be submitted during the presentation and will be addressed at the end of it.

To register for the event, please click here.

For further information please contact:

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com